BeiGene
BeiGene is a life sciences biotechnology company.
BeiGene, founded in October, 2010 and headquartered in Beijing, is an anti-tumor drug developer. The founder is Wu Xiaobin. Listed on the HKEX on August 8, 2018, the company's major shareholders are Beigene, Ltd.. Rivals that have direct and indirect competition with BeiGene include Kintor, HitGen, Aprea Therapeutics, BridgeBio Pharma, etc.
Cancer cell therapy company raised CNY 500 million in D round
Baiji Shenzhou PD-1 inhibitor price dropped by 80%
Novozyme plus R-CHOP Regimen for first-line treatment of mantle cell lymphoma
Bh009 new drug project independently researched and developed by Beihai biological Co., Ltd. was approved by China's clinical trials
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Research
Consumer Staples, Real Estate, Consumer DiscretionaryTech for Global, Globalization Footprints of the Established and the New
Research
Consumer Staples, Real Estate, Consumer DiscretionaryLow-Carbon Industry Expansion - Key Studies From Chinese Companies
Qiuzhen medical and tianguangshi have reached strategic cooperation to develop diagnostic kits and tumor drugs
Sinopharm new coronavirus vaccine approved
Another protein component special medical food was approved, and the total number of approved products increased to 57
Phase I project of Guangzhou Pharmaceutical production base of nuocheng Jianhua was completed
Revenue and Net Profit of Wuxi Apptec Both Increased in 2020
Wuxi apptec said that the main reasons for the company's performance growth were the high growth of laboratories in China and the year-on-year growth of CDMO plate. China laboratory service is the core business of Wuxi apptec, accounting for more than 50% of its revenue. Its main business is small molecule drug discovery, drug analysis and testing.
Apr 01, 2021 04:39 PM
BGI and Hanwei intelligent medical jointly launched mobile "two cancer" intelligent screening
Asc41, a candidate drug for NASH, was administered to overweight and obese subjects in phase IB clinical trial
Fosun medicine: the new crown vaccine has been included in the domestic phase II clinical, and no serious adverse report has been received
Cell and gene therapy cro / cdmo xuanming cells completed a round of financing, led by Huagai capital and juming venture capital
Improving service quality and enabling industrial innovation!
Baiji Shenzhou: midterm analysis of the global phase III clinical trial for the treatment of non-small cell lung cancer reached the main end point
Hillhouse Will Inject USD 1 billion in BeiGene's Share Sale